-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $37

Benzinga·04/08/2026 10:01:41
Listen to the news
Needham analyst Ami Fadia initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $37.